MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: STEMCELL Technologies, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids - Agreement supports further development of organoids as next-generation drug screening platform - HUB4Organoids.eu / STEMCELL.com
The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids

 

NewswireToday - /newswire/ - Utrecht, Netherlands, 2014/01/21 - Agreement supports further development of organoids as next-generation drug screening platform - HUB4Organoids.eu / STEMCELL.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The HUB Foundation for Organoid Technology announced today that it has signed a licensing agreement with STEMCELL Technologies Inc. for the manufacturing and worldwide distribution of cell culture media for growing Organoids. Organoids are mini-organs grown in tissue culture from small pieces of tissue derived from patients with cancer and other diseases, and represent an exciting new tool for scientific research and drug discovery and validation.

“We are pleased that STEMCELL will be our partner in making specialty media for growth of organoids available to the scientific community”, says Prof. Hans Clevers, one of the founding directors of the HUB. “The broad availability of off-the-shelf cell culture media from a world leader in the development of specialized cell culture media and cell separation products represents an essential step in the further implementation of this exciting technology”.

“We are delighted to bring these important culture media products quickly and reliably to researchers for the growth of tissue-specific organoids, and to be the exclusive commercial supplier,” says Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “The first product under this license will be released soon for culture of murine organoids, with products for human tissue to follow”.

About The HUB
The HUB (hub4organoids.eu) is a not-for-profit organization founded by the Royal Netherlands Academy of Sciences and the University Medical Center Utrecht. The HUB exploits the pioneering work of Prof. Hans Clevers who discovered methods to grow stem cell-derived human ‘mini-organs’ (organoids) from tissues of patients with various diseases. The organoids, that are part of the Living Biobank, are characterized by genome sequencing, expression profiling and sensitivity to known and experimental drugs to establish a database linking genetic and transcriptional information to drug responsiveness. The HUB offers licenses to its patented Organoid Technology for drug-screening and access to organoids in the Living Biobank for preclinical drug discovery and validation. In addition, the HUB provides drug screening services to third parties.

About STEMCELL Technologies
STEMCELL Technologies, Inc. (stemcell.com) is a privately-owned biotechnology company that develops specialty cell culture media, cell separation products and ancillary reagents for life science research. Driven by science and a passion for quality, STEMCELL delivers over 1500 products to more than 70 countries worldwide.

Contact Information
The HUB: Dr. Robert Vries
Uppsalalaan 8
3584 CT, Utrecht - The Netherlands
E: info[.]hub4organoids.eu

STEMCELL: Luba Metlitskaia, MSc. - Director, Licensing and Business Development
Suite 400-1618 Station Street
Vancouver, British Columbia Canada
E: bdv[.]stemcell.com

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: STEMCELL Technologies, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


The HUB Foundation for Organoid Technology and STEMCELL Technologies Sign Agreement on the Manufacturing of Cell Culture Media for Organoids

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Press Office - Stemcell.com 
604-877-0713 marketing[.]stemcell.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any STEMCELL Technologies, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From STEMCELL Technologies, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM and Avril Complete Creation of Joint Venture to Develop Plant-based Protein
Ipsen Joins Clinical Collaboration to Evaluate Cabozantinib (CABOMETYX®) Plus Atezolizumab in Metastatic Non-small Cell Lung Cancer
Stevanato Group, SCHOTT, and Gerresheimer Confirm the Readiness to Support Future Covid-19 Vaccine with Pharmaceutical Containers
Ipsen Receives FDA Fast Track Designation for Liposomal Irinotecan (ONIVYDE®) as A First-line Combination Treatment for Metastatic Pancreatic Cancer
Ipsen Demonstrates Continued Commitment to Rare Diseases with Eight Abstracts Accepted At ENDO 2020 Published in the Journal of the Endocrine Society
Waters Corporation Earns New Product Innovation Award with First SmartMS-enabled Biopharmaceutical Solution
DSM Boosts Maternal and Infant Nutrition Portfolio with New Plant-based High Potency DHA Oil
Ipsen Enters into an Option Agreement with IRICoR and Université de Montréal for A Discovery-stage Oncology Program
Ipsen Announces Positive Topline Results from Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX®
Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  RightITnow, Inc.





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)